Key Takeaways
- The FDA advisory committee voted unanimously in favor of Moderna’s mRNA flu vaccine, mFlusiva, for adults aged 50 and older.
- Panel discussions highlighted the potential for mRNA vaccines to provide quicker production and better matching to circulating flu strains.
- Moderna aims to expand its portfolio beyond COVID-19 and RSV vaccines, eyeing growth in oncology and rare diseases.
FDA Approval Steps for Moderna’s mRNA Flu Vaccine
Moderna’s journey to expand its mRNA technology into the influenza vaccination market reached an important milestone when the FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously to endorse its mRNA flu vaccine, mFlusiva (mRNA-1010), for individuals aged 50 and above. The committee voted 9-0 for two age groups: 50-64 and those aged 65 and older, concluding that the vaccine’s benefits outweigh its risks.
During the panel discussion, experts analyzed the vaccine’s efficacy, safety data, and its potential role against the backdrop of existing influenza vaccination options. While several influenza vaccines are available, advocates for Moderna’s candidate noted that the mRNA approach could facilitate faster production, allowing for better alignment with the circulating influenza strains each year.
Moderna’s Dr. Rituparna Das emphasized the advantages of mRNA-1010, stating that the technology could sidestep the limitations of traditional vaccines, which often suffer delays due to the time between strain selection and vaccination. By encoding the chosen antigen sequence directly, mRNA could enhance the manufacturing process and provide stronger protection for populations burdened by influenza.
In Phase 3 trials, mRNA-1010 exhibited a relative efficacy 26.6% higher than a standard-dose licensed vaccine for adults over 50. Common adverse reactions included injection site pain, fatigue, headache, and myalgia, but the company noted no significant differences in serious adverse events across the trial groups. Panelist Adam Berger acknowledged that, despite concerns regarding the short duration of the trial, the data largely supported the vaccine’s safety and effectiveness, emphasizing the encouraging efficacy compared to existing influenza vaccines.
Moderna’s application for the mRNA flu vaccine approval faced initial hurdles in February when the FDA refused to file the application due to concerns about the Phase 3 trial design. The agency recommended that Moderna use a more robust standard of care for older adults. However, after discussions between the two parties, the FDA eventually accepted the application.
To navigate the regulatory landscape, Moderna proposed a dual-pathway approach during its meeting with the FDA. This involves seeking traditional approval for adults over 50, alongside a request for accelerated approval for individuals aged 65 and older, with a commitment to conduct confirmatory trials.
As Moderna seeks to diversify its vaccine offerings beyond its COVID-19 and RSV shots, the advisory committee’s vote signifies a step toward a broader vision. The company recently appointed a new commercial chief and heightened the responsibilities of its president to prepare for multiple upcoming launches.
In addition to its flu, COVID-19, and norovirus candidates, Moderna aims to expand its reach in oncology and rare diseases. Analysts from Evercore ISI noted that gaining FDA approval for the flu vaccine could help Moderna reinstate growth while its oncology division matures, although they cautioned that the flu program alone wouldn’t be a game changer for the company.
The content above is a summary. For more details, see the source article.